"Resection Rate of Locally Advanced Pancreatic Cancer in Gemcitabine plus Nab-Paclitaxel Versus FOLFIRINOX" by Ripal Gandhi

Selected Works of Ripal Gandhi

Follow Contact

Presentation

Resection Rate of Locally Advanced Pancreatic Cancer in Gemcitabine plus Nab-Paclitaxel Versus FOLFIRINOX

American Society of Clinical Oncology (ASCO) Virtual Gastrointestinal Cancers Symposium (2021)

Ripal Gandhi, Baptist Health South Florida

Disciplines

Medicine and Health Sciences

Publication Date

January 17, 2021

Comments

Additional Authors: Sharif S, Zureikat AH, Novelli PM, Lopez CD, Kardosh A, Chung KY, Jones WB, Hatoum H,

Meredith KL, Zervos EE, Ucar A, Nazemzadeh R, Kasi PM, Vandestraeten E, Decaestecker J, Delaunoit T, Li CC, Agah R, Pishvaian M.

Citation Information

Ripal Gandhi. "Resection Rate of Locally Advanced Pancreatic Cancer in Gemcitabine plus Nab-Paclitaxel Versus FOLFIRINOX" American Society of Clinical Oncology (ASCO) Virtual Gastrointestinal Cancers Symposium (2021)
Available at: http://works.bepress.com/ripal-gandhi/176/